NEW YORK (360Dx) – The US Food and Drug Administration today said it has allowed for the first time the marketing of a blood test to evaluate mild traumatic brain injury, more commonly known as a concussion.

The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood from the brain within 12 hours of head injury. Levels of these proteins after a concussion can be used to predict which patients have intracranial lesions visible by CT scan and which don't, the FDA said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.